ArticleQatar medical journal2022
First allergy conference in Qatar: Let's explore allergy with a new lens.
Article in Qatar medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic diseases are common medical conditions that now show an increasing trend globally and contributes to poor quality of life of the affected individual. Allergies can be fatal in a few instances such as anaphylaxis, severe asthma, and hereditary angioedema if the symptoms are not recognized and treated correctly. (1, 2) The first Allergy Conference in Qatar aimed to highlight the burden of allergic diseases in Qatar and globally with a special focus on educating both the physicians and the community. The preparation for this conference over the past three years threw up a few challenges, mainly owing to the coronavirus disease 2019 (COVID-19) pandemic that affected all forms of face-to-face interactions and social gatherings. Therefore, our conference was held virtually on February 05, 2022, which was more than two years from the first planned date. The conference was sponsored by the Hamad Medical Corporation in partnership with the Qatar Allergy and Immunology Society. In our scientific program, the scientific committees selected topics related to 3 major areas in allergy practice (systemic, respiratory, and skin allergy disorders). Abstract submissions were encouraged in areas related to audits, case reports, service development, and clinical and basic research in the field of allergy. Additional topics were included related to the current COVID-19 pandemic and COVID-19 vaccinations. We received 34 abstracts and accepted 28 for poster abstracts. Among them, 6 received approval for oral presentations; and 6 (21.4%) had the term COVID-19 or SARS-CoV-2 in their title, which supported the burden related to COVID-19 in our community and association between this new pandemic and our allergy practice and disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.